A5019965376- Bacterial Infections and Vaccines
- Pneumonia and Respiratory Infections
- Hepatitis B Virus Studies
- Vaccine Coverage and Hesitancy
- Influenza Virus Research Studies
- Clostridium difficile and Clostridium perfringens research
- Hepatitis Viruses Studies and Epidemiology
- SARS-CoV-2 and COVID-19 Research
- Pharmaceutical studies and practices
- Hepatitis C virus research
- Viral gastroenteritis research and epidemiology
- Respiratory viral infections research
- Immunodeficiency and Autoimmune Disorders
- Diphtheria, Corynebacterium, and Tetanus
- Immunotherapy and Immune Responses
GlaxoSmithKline (Belgium)
2017-2021
Combined hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliomyelitis and Haemophilus influenzae type b vaccine (DTaP-HBV-IPV/Hib) can further reduce the number of injections in pediatric immunization schedules countries currently using pentavalent DTaP combination vaccines. This open-label, randomized, multicenter study (NCT02096263) conducted United States evaluated immunogenicity safety DTaP-HBV-IPV/Hib compared with concomitant administration DTaP-HBV-IPV Hib
We evaluated antibody persistence against hepatitis B virus (HBV) in adolescents previously vaccinated with a hexavalent diphtheria-tetanus-acellular pertussis-HBV-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine (DTPa-HBV-IPV/Hib), as part of the national newborn immunization program Germany. also assessed anamnestic response to challenge dose monovalent HBV vaccine. In this phase 4, open-label, non-randomized study (NCT02798952), 302 aged 14-15 years, primed their...
We assessed the immunogenicity and safety of combined diphtheria-tetanus-acellular pertussis-inactivated poliovirus/Haemophilus influenzae type b vaccine (DTPa-IPV/Hib) in children Russian Federation aiming to support registration Russia. In this phase 3, non-randomized, open-label study (NCT02858440), healthy received three primary doses at 4.5, 6 months age (N = 235) a booster dose 18 225). Seroprotection rates against diphtheria, tetanus, Hib, poliovirus 1–3, seropositivity pertussis...
Safety and immunogenicity of 2 investigational formulations diphtheria, tetanus Haemophilus influenzae type b antigens the combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliomyelitis-Hib vaccine (DTPa-HBV-IPV/Hib) were evaluated in a Primary (NCT01248884) Booster vaccination (NCT01453998) study.In study, 721 healthy infants (randomized 1:1:1) received 3 doses DTPa-HBV-IPV/Hib formulation A (DATAPa-HBV-IPV/Hib), or B (DBTBPa-HBV-IPV/Hib) licensed (Infanrix hexa, GSK;...